Amgen AMGN
NASDAQ AMGN
$469.32 +1.21 (+0.26%)
As of: Nov 12, 2026 · 10:21 AM EST

Amgen (AMGN) Receivables - Other (2013)

Updated

Amgen's Receivables - Other came in at $22 million for Q4 2013.

Analysis

Amgen (AMGN) Receivables - Other (2013) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Vertex Pharmaceuticals 138.90 Bn 106.64 Bn 2.91 Bn
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2013 22.00 Mn
Sep 30, 2013 560.00 Mn
API Access

Amgen Receivables - Other API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables-other&ticker=AMGN&period=max&api_key=YOUR_API_KEY